Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

As Healio previously reported, in the main results of NODE-301, etripamil (Millstone Pharmaceuticals), an L-type calcium channel blocker administered via nasal spray, missed the primary endpoint of ...

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...

DUBLIN--(BUSINESS WIRE)--The "Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. A detailed picture of the Paroxysmal ...

CHICAGO -- The investigational L-type calcium channel blocker etripamil, formulated as a self-administered nasal spray, shortened spontaneous paroxysmal supraventricular tachycardia episodes among ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

According to DelveInsight's estimates, the paroxysmal supraventricular tachycardia market in the 7MM is expected to show positive growth, during the forecast period (2024–2034), mainly attributed to ...

(MENAFN- GetNews) DelveInsight's "Paroxysmal Supraventricular Tachycardia (PSVT) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Paroxysmal ...

According to DelveInsight's estimates, the paroxysmal supraventricular tachycardia market in the 7MM is expected to show positive growth, during the forecast period (2024-2034), mainly attributed to ...